B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ABCC4

MOLECULAR TARGET

ATP binding cassette subfamily C member 4 (PEL blood group)

UniProt: O15439NCBI Gene: 1025719 compounds

ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ABCC4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Alprostadil1.102
2Dehydroepiandrosterone Sulfate1.102
3Rimonabant1.102
4amlexanox0.691
5Camptothecin0.691
6cefaclor0.691
7Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as0.691
8Cefmetazole0.691
9Cefoperazone Semisynthetic broad-spectrum cephalosporin with0.691
10Cefoxitin0.691
11Ceftriaxone0.691
12cefuroxime0.691
13Cephradine0.691
14Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate).0.691
15Dinoprostone0.691
16Doxazosin0.691
17Febuxostat0.691
18felbinac0.691
19Tubocurarine0.691

About ABCC4 as a Drug Target

ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented ABCC4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ABCC4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.